These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The alleged dopamine D1 receptor agonist SKF 83959 is a dopamine D1 receptor antagonist in primate cells and interacts with other receptors. Andringa G; Drukarch B; Leysen JE; Cools AR; Stoof JC Eur J Pharmacol; 1999 Jan; 364(1):33-41. PubMed ID: 9920182 [TBL] [Abstract][Full Text] [Related]
23. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development. Neal-Beliveau BS; Joyce JN Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220 [TBL] [Abstract][Full Text] [Related]
24. Clozapine antagonism of D-1 and D-2 dopamine receptor-mediated behaviors. Criswell HE; Mueller RA; Breese GA Eur J Pharmacol; 1989 Jan; 159(2):141-7. PubMed ID: 2495973 [TBL] [Abstract][Full Text] [Related]
25. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Crotty K; Mueller RA J Pharmacol Exp Ther; 1984 Nov; 231(2):343-54. PubMed ID: 6149306 [TBL] [Abstract][Full Text] [Related]
26. The role of the phosphatidyinositol-linked D1 dopamine receptor in the pharmacology of SKF83959. Zhen X; Goswami S; Friedman E Pharmacol Biochem Behav; 2005 Apr; 80(4):597-601. PubMed ID: 15820529 [TBL] [Abstract][Full Text] [Related]
28. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output. Huang KX; Walters JR J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456 [TBL] [Abstract][Full Text] [Related]
29. Grooming in the mouse is stimulated by the dopamine D1 agonist SKF 38393 and by low doses of the D1 antagonist SCH 23390, but is inhibited by dopamine D2 agonists, D2 antagonists and high doses of SCH 23390. Starr BS; Starr MS Pharmacol Biochem Behav; 1986 Apr; 24(4):837-9. PubMed ID: 2940604 [TBL] [Abstract][Full Text] [Related]
30. Co-activation of D1- and D2-like receptors is unnecessary for stimulated motor behavior in rats depleted of dopamine during development. Byrnes EM; Abrams D; Bruno JP Behav Brain Res; 1994 Apr; 61(2):205-14. PubMed ID: 7913605 [TBL] [Abstract][Full Text] [Related]
31. Dopamine depletion preferentially impairs D1- over D2-receptor regulation of striatal in vivo acetylcholine release. Bertorelli R; Zambelli M; Di Chiara G; Consolo S J Neurochem; 1992 Jul; 59(1):353-7. PubMed ID: 1351928 [TBL] [Abstract][Full Text] [Related]
32. Neurotransmitter changes in the pathophysiology of Lesch-Nyhan syndrome. Saito Y; Takashima S Brain Dev; 2000 Sep; 22 Suppl 1():S122-31. PubMed ID: 10984673 [TBL] [Abstract][Full Text] [Related]
33. Sleep during acute dopamine D1 agonist SKF 38393 or D1 antagonist SCH 23390 administration in rats. Monti JM; Fernández M; Jantos H Neuropsychopharmacology; 1990 Jun; 3(3):153-62. PubMed ID: 2141985 [TBL] [Abstract][Full Text] [Related]
34. SKF 83959 is an antagonist of dopamine D1-like receptors in the prefrontal cortex and nucleus accumbens: a key to its antiparkinsonian effect in animals? Cools AR; Lubbers L; van Oosten RV; Andringa G Neuropharmacology; 2002 Feb; 42(2):237-45. PubMed ID: 11804620 [TBL] [Abstract][Full Text] [Related]
36. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation. Hu XT; White FJ Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677 [TBL] [Abstract][Full Text] [Related]
37. Topography of dopamine behaviours mediated by D1 and D2 receptors revealed by intrastriatal injection of SKF 38393, lisuride and apomorphine in rats with a unilateral 6-hydroxydopamine-induced lesion. Fletcher GH; Starr MS Neuroscience; 1987 Feb; 20(2):589-97. PubMed ID: 2953990 [TBL] [Abstract][Full Text] [Related]
38. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. Criswell HE; Johnson KB; Mueller RA; Breese GR J Pharmacol Exp Ther; 1993 May; 265(2):1001-10. PubMed ID: 8098756 [TBL] [Abstract][Full Text] [Related]
39. Involvement of central dopamine and D1 receptors in stress-induced colonic motor alterations in rats. Bueno L; Gue M; Fabre C; Junien JL Brain Res Bull; 1992 Aug; 29(2):135-40. PubMed ID: 1356067 [TBL] [Abstract][Full Text] [Related]
40. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate. Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD Psychopharmacology (Berl); 1995 Feb; 117(4):403-12. PubMed ID: 7604140 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]